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Abstract: Cellular therapy is the replacement of unhealthy or damaged cells or tissues by new 
ones. Because neurodegenerative diseases, cerebral strokes, and traumatic injuries to the central 
nervous system (CNS) produce neurological deﬁ  cits that result from neuronal loss, cell therapy is 
a prominent area of investigation for the treatment of neurological diseases and injuries. Neural 
progenitor and stem cells generate the main phenotyes of the nervous system, and offer a model 
of choice for cellular therapy in the CNS. With the conﬁ  rmation that neurogenesis occurs in 
the adult brain, and the recent isolation and characterization in vitro of neural progenitor and 
stem cells from the adult CNS, new strategies are being devised and have the potential to treat 
a broad range of CNS diseases and injuries.
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Introduction
Neural stem cells (NSCs) are selfrenewing multipotent cells that generate the main 
phenotype of the nervous system, neurons, astrocytes, and oligodendrocytes. Neural 
progenitor cells are more mature multipotent cells with limited proliferative capacity; 
they are generated through transient ampliﬁ  cation of NSCs. Contrary to a long held 
dogma, neurogenesis occurs throughout adulthood in the mammalian brain and NSCs 
reside in the adult CNS (Gage 2000; Gross 2000), including human (Eriksson et al 
1998; Curtis et al 2007). Neurogenesis occurs primarily in two areas of the adult mam-
malian brain, the dentate gyrus (DG) of the hippocampus and the subventricular zone 
(SVZ). In the DG, newly generated neuronal cells in the subgranular zone migrate 
to the granular layer, where they differentiate into mature neuronal cells, and extend 
axonal projections to the CA3 area. In the SVZ, cells are generated in the anterior 
part of the SVZ, and migrate to the olfactory bulb (OB), through the rostro-migratory 
stream (RMS), where they differentiate into interneurons of the OB. In human, the RMS 
is organized, differently than in other species, around a lateral ventricular extension 
reaching the OB (Curtis et al 2007).
It is hypothesized that neurogenesis originate from residual stem cells in the adult 
brain. Self-renewing multipotent NSCs have been isolated and characterized in vitro 
from various areas of the adult CNS, suggesting that NSCs reside throughout the 
CNS and providing valuable sources of material for cellular therapy (Taupin and 
Gage 2002). Cell therapeutic interventions may involve both in vivo stimulation and 
transplantation of neural progenitor and stem cells of the adult brain.
Stimulation of endogenous neural progenitor
and stem cells
The adult CNS is seeded with neural progenitor and stem cells. The stimulation of these 
cells would represent a strategy to promote regeneration in the diseased and injured Biologics: Targets & Therapy 2007:1(1) 54
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CNS. This has been particularly studied in animal models 
of Parkinson’s disease (PD). In a recent study that report the 
generation of new dopaminergic neuronal cells in the adult rat 
substantia nigra (SN), the authors have investigated the gen-
eration of new dopaminergic neuronal cells following lesion 
of the SN (Zhao et al 2003). The rate of neurogenesis, as 
measured by BrdU labeling, was reported to be increased by 
2-fold, 3 weeks following lesion induced by a systemic dose 
of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), 
a model of PD. In contrast, a more recent study found 
no evidence of new dopaminergic neurons in the SN of 
6-hydroxydopamine-lesioned hemi-Parkinsonian rodents 
(Frielingsdorf et al 2004). Furthermore, the generation of 
new dopaminergic neurons in the adult SN remains source 
of controversy (Lie at al 2002; Frielingsdorf et al 2004). 
Though the generation of new dopaminergic neuronal cells 
in the adult SN remains to be conﬁ  rmed, hypothetically, 
regeneration could be promoted locally by stimulating neu-
ral progenitor and stem cells at sites of degeneration. It is 
the premise of cellular therapy that the environment would 
contribute to the development and integration of the cells in 
the tissue (Watt and Hogan 2000).
Investigators are aiming to identify factors promoting 
adult neurogenesis and the intregration of new neuronal 
cells after lesion. Factors like platelet-derived growth 
factor (PDGF-BB) and brain-derived neurotrophic factor 
(BDNF) induce striatal neurogenesis in adult rats with 
6-hydroxydopamine lesions, with no indications of any 
newly born cells differentiating into dopaminergic neurons 
following growth factor treatment (Mohapel et al 2005). Such 
factors may prove to be beneﬁ  cial for recovery in PD. The 
stimulation of endogenous neural progenitor and stem cells 
has also been reported in other models of CNS injuries. The 
implantation of dendritic cells, antigen-presenting cells of the 
immune system, in the spinal cord after injury in adult mice 
stimulates neurogenesis de novo, and locomotor recovery. 
Histological analysis suggests that the dendritic cells, by 
releasing trophic factors, may have induced regeneration of 
the corticospinal tract axons (Mikami et al 2004).
Alternatively, new neuronal cells are generated at sites 
of degeneration in the diseased brain and after CNS injuries, 
and originate from the SVZ. Curtis and colleagues (2003) 
and Tattersﬁ  eld and colleagues (2004) reported an increase 
in SVZ neurogenesis, leading to the migration of neural 
progenitor cells and the formation of new neuronal cells 
to damaged areas of the striatum in Huntington’s disease 
(HD) patients and in animal model of HD (quinolinic acid 
lesion). After experimental strokes (middle cerebral artery 
occlusion), new neuronal cells are detected at the major 
sites of degeneration, like the striatum and cortex distal to 
the infarction (Jiang et al 2001; Zhang et al 2001; Li et al 
2002; Parent et al 2002). Cell tracking studies revealed that 
newly generated neuronal cells migrate partially through 
the RMS to the sites of degeneration, where they differenti-
ate into the phenotypes of the degenerated nerve cells. It is 
estimated that 0.2% of the degenerated nerve cells in the 
striatum after focal ischemia are replaced (Arvidsson et al 
2002; Jin et al 2003).
Hence, neurogenesis is stimulated in the adult CNS after 
injury, and new neuronal cells are generated at the sites of 
degeneration. The identiﬁ  cation of the SVZ as the source of 
neural progenitor and stem cells with regenerative potential 
after injury suggests that strategies to promote regeneration 
and repair may focus on stimulating SVZ neurogenesis after 
injury. Both environmental enrichment and administration 
of various factors and molecules have been reported to 
promote SVZ neurogenesis. The rate of cell proliferation 
in the SVZ increases following exposure to an environment 
enriched in odors (Rochefort et al 2002). Trophic factors, like 
epidermal growth factor (EGF) and basic ﬁ  broblast growth 
factor (FGF-2) (Craig et al 1996; Kuhn et al 1997; Wagner 
et al 1999), and other factors, like Ginkgo biloba extract 
(Didier et al 2002), have also been reported to stimulate 
SVZ neurogenesis in rodents. Transforming growth factor-α 
(TGF-α) infusion into the adult rat striatum leads to migration 
of neuronal progenitor cells from the SVZ to the infusion 
site (Fallon et al 2000). These molecules and factors are 
potential candidates to recruit new neuronal cells from the 
SVZ for cellular therapy in the CNS. Future investigations 
will aim at identifying factors promoting neurogenesis in 
the degenerated areas.
The identiﬁ  cation of the SVZ as a source of newly generated 
neuronal cells at the sites of degeneration after injuries presents 
several features that can beneﬁ  t cellular therapy in the CNS. 
First, in the intact CNS and after injury, a signiﬁ  cant propor-
tion of newly generated neuronal progenitor cells in the SVZ 
undergo programmed cell death rather than achieving maturity, 
eg, 80% of the new striatal neuronal cells that are generated 
from the SVZ after stroke in rats die within the ﬁ  rst weeks after 
the insult (Morshead et al 1992; Arvidsson et al 2001; Cameron 
and McKay 2001). This transient increase in newly generated 
neural progenitor cells provides a window of opportunity when 
newly generated neural progenitor cells could be salvaged, and 
directed to participate to the regeneration of the damaged tissue. 
Factors preventing cell death, like caspases (Namura et al 1998; 
Pompeiano et al 2000; Ekdahl et al 2001), would thus also be Biologics: Targets & Therapy 2007:1(1) 55
Therapeutic potential of adult NSCs
potentially beneﬁ  cial for cellular therapy, alone or in combination 
with the administration of trophic factors, and environmental 
enrichment that promote SVZ neurogenesis (Craig et al 1996; 
Kuhn et al 1997; Wagner et al 1999; Didier et al 2002; Roche-
fort et al 2002). Second, the identiﬁ  cation of the SVZ, along the 
ventricles, as the source of neural progenitor and stem cells with 
regenerative potential after injury also suggests that molecules 
and factors could be administered either by systemic injection, 
intracerebroventricular, subcutaneous injection, or through the 
cerebrospinal ﬂ  uid (CSF) to promote neurogenesis in the brain 
(Craig et al 1996; Kuhn et al 1997; Wagner et al 1999), but 
also the spinal cord (Martens et al 2002), as the central canal 
is a presumed location of putative NSCs (Horner et al 2000). 
Procedures that are less invasive would be beneﬁ  cial for the 
treatment of the injured patients. In support to this contention, 
intrvavenous administration of brain-derived neurotrophic fac-
tor stimulates neurogenesis in the DG and enhances migration 
of subventricular zone progenitor cells to the nearby damaged 
striatum after ischemic stroke (Schabitz et al 2007).
Transplantation of adult-derived 
neural progenitor and stem cells
Neural progenitor and stem cells have been isolated and 
cultured in vitro from various areas of the adult CNS, 
including the spinal cord, and from various species (Taupin 
and Gage 2002), including from human biopsies and post-
mortem tissues (Palmer et al 2001; Roisen et al 2001; 
Schwartz et al 2003), potentially allowing the generation of 
neural progenitor and stem cells from multiple sources for 
cellular therapy. Adult neural progenitor and stem cells could 
also be isolated from the an undamaged area of the patient’s 
brain, expanded in vitro, and grafted back to the degenerated 
area(s), allowing autologous transplantation. This would 
obviate the need to ﬁ  nd a matching donor and to administer 
drugs that suppress the immune system, like cyclosporine, 
to prevent tissue rejection. However, risk associated with 
invasive surgical procedure that would probably involves 
the destruction of healthy brain tissue, limits the clinical 
application of such strategy.
In all this shows that adult derived-NSCs represent 
a potent model for cellular therapy. Recent studies have 
conﬁ  rmed the engraftment potential of adult derived neural 
progenitor and stem cells in animal studies (Gage et al 1995; 
Suhonen et al 1996; Shihabuddin et al 2000; Akiyama et al 
2001; Wu et al 2001; Zhang et al 2003), conﬁ  rming their 
potential for cellular therapy.
Cell transplantation aims mainly at delivering cells at 
speciﬁ  c sites. This is particularly suitable for the treatment 
of diseases, and injuries where the degeneration is limited to 
mainly one area, like for neurodegenerative diseases as PD 
and after traumatic injury to the CNS (Armstrong et al 2003; 
Lepore et al 2005). When the degeneration is widespread, 
as in neurodegenerative diseases like Alzheimer’s disease, 
HD and multiple sclerosis, such strategy is not applicable. 
Neural progenitor and stem cells migrate to tumor (Aboody 
et al 2000; Brown et al 2003; Glass et al 2005), injured 
(Macklis et al 1993; Veizovic et al 2001; Modo et al 2004; 
Boockvar et al 2005), diseased sites (Pluchino et al 2003), 
when transplanted in the CNS, or administered either by 
systemic injection, or through the cerebrospinal ﬂ  uid (CSF) 
by injecting cells into the 4th ventricle in the rat. The injected 
cells conveyed to the damaged areas, where they integrate 
the host tissue. A recent study has reported that the systemic 
injection of neural progenitors and stem cells may provide 
signiﬁ  cant clinical beneﬁ  ts in an animal model of multiple 
sclerosis (Pluchino et al 2003). Thus, NSC therapy may pro-
vide a therapeutic tool for the treatment of a broad range of 
neurological diseases and injuries. Such migratory properties 
of NSCs can be used as a general mode for administering 
neural progenitor and stem cells for cellular therapy, avoiding 
surgical procedures, and their associated risks and second-
ary effects. Hence, systemic injection and injection through 
CSF are regarded as promising ways to administer NSCs for 
cellular therapy, particularly for the treatment of spinal cord 
injuries (Wu et al 2002; Fujiwara et al 2004).
Adult neural progenitor and stem cells can be genetically 
modiﬁ  ed by retroviral-mediated infection, rendering them a 
vehicle for gene therapy. Mouse and human neural progenitor and 
stem cells genetically modiﬁ  ed to express acid sphingomyelinase 
reverse lysosomal storage pathology when transplanted into ani-
mal models of Niemann-Pick’s disease (Shihabuddin et al 2004; 
Sidman et al 2007). This highlights the potential of genetically 
modiﬁ  ed NSCs for the treatment of lysosomal storage diseases 
and other genetic diseases of the CNS. The potential of geneti-
cally modiﬁ  ed NSCs is further highlighted by their potential for 
the treatment of brain tumors. Grafted neural progenitor and stem 
cells migrate to tumors. The properties of NSCs to be genetically 
modiﬁ  ed and to migrate to tumor sites have been proposed for 
the treatment of brain tumors. It is proposed to genetically modi-
ﬁ  ed NSCs with “suicide genes”, like genes coding for cytolytic 
activities or anti-tumor cytokines, to attack and destroy brain 
tumor cells. Intravascular administration of neural progenitor and 
stem cells genetically engineered to express interferon-b lead to 
tumor regression in mice (Kim et al 2006; Dickson et al 2007). 
This strategy further extends the use of cell engineering of NSCs 
for cancer therapy in the CNS.Biologics: Targets & Therapy 2007:1(1) 56
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Altogether these data show that cell transplantation of 
adult NSCs provide a model of choice for cellular therapy 
in the CNS, and has the potential to treat a broad range of 
CNS diseases and injuries, ranging from neurodegenerative 
diseases, strokes, spinal cord injuries, genetic diseases of the 
CNS, to brain tumors.
In a study where human fetal neural progenitor and 
stem cells were injected after spinal cord injury in mice, 
the improvements in walking disappeared following treat-
ment with diphtheria toxin, which kills only human cells 
and not mouse cells (Cummings et al 2005). This suggests 
that the grafted neural progenitor and stem cells themselves 
are responsible for recovery. Beside the replacement of the 
degenerated cells by the grafted cells, grafted NSCs may also 
promote functional recovery by promoting the survival of 
injured neuronal cells through the secretion of neurotrophic 
factors (Ourednik et al 2002; Lu et al 2003; Llado et al 2004; 
Pfeifer et al 2004; Yan et al 2004), and its interaction with the 
injured brain and immune system (Park et al 2002; Pluchino 
et al 2005), further underlining the relevance of NSCs for 
cellular therapy in the CNS.
Conclusion
Because of their potential to generate the different cell 
types of the CNS, NSCs represent a model of choice for 
cellular therapy in the CNS. The recent conﬁ  rmation that 
neurogenesis occurs in the adult brain and NSCs reside in 
the adult CNS opens new opportunities for cellular therapy. 
On the one hand, new neuronal cells are generated at the sites 
of degeneration in the diseased and injured brain. Though 
the CNS has limited capacity to recover after injury, the data 
shows that the CNS has the ability to repair itself after injury. 
On the other hand, the grafting of adult neural progenitor 
and stem cells offers an alternative for cellular therapy in the 
CNS. Hence, adult NSCs offer a potent and promising model 
for cellular therapy. Futures studies will aim at identifying 
the factors and mechanisms underlying adult neurogenesis, 
to promote and enhance the regenerative potential of endog-
enous NSCs. Isolated adult neural progenitor and stem cell 
populations are heterogeneous, likely a factor limiting their 
potential for recovery. Future studies will aim at identify-
ing the NSCs, enriched them, as a source of homogeneous 
populations of NSCs for cellular therapy. Futures directions 
will aim at addressing the challenges and limitations of adult 
NSC therapy. Particularly, to what extent newly formed or 
transplanted neural progenitor and stem cells integrate and 
become functional? What are the potential and risk that 
newly formed or transplanted neural progenitor and stem 
cells establish the wrong connections or transplanted neural 
progenitor and stem cells develop into tumors upon grafting? 
These questions will need to be answered before the adult 
NSCs could be brought to therapy.
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